title: Polycystic kidney disease and therapeutic approaches.
abstract: Polycystic kidney disease (PKD) is a common genetic disorder in which extensive epithelial-lined cysts develop in the kidneys. In previous studies, abnormalities of polycystin protein and its interacting proteins, as well as primary cilia, have been suggested to play critical roles in the development of renal cysts. However, although several therapeutic targets for PKD have been suggested, no early diagnosis or effective treatments are currently available. Current developments are active for treatment of PKD including inhibitors or antagonists of PPAR-γ, TNF-α, CDK and VEGF. These drugs are potential therapeutic targets in PKD, and need to be determined about pathological functions in human PKD. It has recently been reported that the alteration of epigenetic regulation, as well as gene mutations, may affect the pathogenesis of PKD. In this review, we will discuss recent approaches to PKD therapy. It provides important information regarding potential targets for PKD.
authors.affiliation: Department of Biological Science, Sookmyung Women's University, Seoul 140-742, Korea.
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Park
authors.forename: Yu Mi
authors.initials: YM
authors.lastname: Woo
authors.forename: Jong Hoon
authors.initials: JH
authors.lastname: Park
mesh_terms: D000818:Animals; D044127:Epigenesis, Genetic; D056572:Histone Deacetylase Inhibitors / Q000378:metabolism; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism; D007690:Polycystic Kidney Diseases / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D056572:Histone Deacetylase Inhibitors; D035683:MicroRNAs; D047495:PPAR gamma; D014409:Tumor Necrosis Factor-alpha; D006655:Histone Deacetylases